Gliknik is focused on immune modulation, developing an immunomodulator platform, a platform of recombinant drugs designed to mimic the eficacy of pooled human Intravenous Immunoglobulin, and a platform that produces compounds that are similar to moncolonal antibodies but designed to have increased tumor cell killing.
|